SEC Info - Puma Biotechnology, Inc. - ‘10-K’ for 12/31/23

SEC Info℠

Home

My Interests

Help

Please Sign In

Puma Biotechnology, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Thursday, 2/29/24, at 4:41pm ET · For: 12/31/23 · Accession #: 1437749-24-6121 · File #: 1-35703

Previous ‘10-K’: ‘10-K’ on 3/2/23 for 12/31/22 · Latest ‘10-K’: This Filing · 44 References:

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Puma Biotechnology, Inc.          10-K       12/31/23   90:9.8M                                   RDG Filings/FA

Annual Report — Form 10-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.32M 
 2: EX-21.1     Subsidiaries List                                   HTML     25K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     24K 
 8: EX-97.1     Exhibit 97.1 Puma Biotechnology, Inc. Policy for    HTML     38K 
                Recovery of Erroneously Awarded Compensation                     
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     26K 
14: R1          Document And Entity Information                     HTML     95K 
15: R2          Consolidated Balance Sheets                         HTML    133K 
16: R3          Consolidated Balance Sheets (Parentheticals)        HTML     36K 
17: R4          Consolidated Statements of Operations               HTML    105K 
18: R5          Consolidated Statements of Comprehensive Income     HTML     44K 
                (Loss)                                                           
19: R6          Consolidated Statements of Stockholders' Equity     HTML     73K 
                (Deficit)                                                        
20: R7          Consolidated Statements of Stockholders' Equity     HTML     26K 
                (Deficit) (Parentheticals)                                       
21: R8          Consolidated Statements of Cash Flows               HTML    132K 
22: R9          Insider Trading Arrangements                        HTML     66K 
23: R10         Note 1 - Business and Basis of Presentation         HTML     38K 
24: R11         Note 2 - Significant Accounting Policies            HTML    176K 
25: R12         Note 3 - Accounts Receivable                        HTML     37K 
26: R13         Note 4 - Prepaid Expenses and Other                 HTML     40K 
27: R14         Note 5 - Property and Equipment                     HTML     37K 
28: R15         Note 6 - Leases                                     HTML     45K 
29: R16         Note 7 - Intangible Assets                          HTML     37K 
30: R17         Note 8 - Accrued Expenses                           HTML     49K 
31: R18         Note 9 - Debt                                       HTML     52K 
32: R19         Note 10 - Stockholders' Equity (Deficit)            HTML    121K 
33: R20         Note 11 - 401(k) Savings Plan                       HTML     29K 
34: R21         Note 12 - Income Taxes                              HTML    112K 
35: R22         Note 13 - Commitments and Contingencies             HTML     65K 
36: R23         Significant Accounting Policies (Policies)          HTML    231K 
37: R24         Note 2 - Significant Accounting Policies (Tables)   HTML     99K 
38: R25         Note 3 - Accounts Receivable (Tables)               HTML     35K 
39: R26         Note 4 - Prepaid Expenses and Other (Tables)        HTML     39K 
40: R27         Note 5 - Property and Equipment (Tables)            HTML     35K 
41: R28         Note 6 - Leases (Tables)                            HTML     42K 
42: R29         Note 7 - Intangible Assets (Tables)                 HTML     38K 
43: R30         Note 8 - Accrued Expenses (Tables)                  HTML     44K 
44: R31         Note 9 - Debt (Tables)                              HTML     43K 
45: R32         Note 10 - Stockholders' Equity (Deficit) (Tables)   HTML    118K 
46: R33         Note 12 - Income Taxes (Tables)                     HTML    109K 
47: R34         Note 1 - Business and Basis of Presentation         HTML     48K 
                (Details Textual)                                                
48: R35         Note 2 - Significant Accounting Policies (Details   HTML    107K 
                Textual)                                                         
49: R36         Note 2 - Significant Accounting Policies -          HTML     33K 
                Potentially Dilutive Securities Not Included in                  
                Calculation of Diluted Net Loss per Share                        
                (Details)                                                        
50: R37         Note 2 - Significant Accounting Policies - Assets   HTML     49K 
                Measured at Fair Value on Recurring Basis                        
                (Details)                                                        
51: R38         Note 2 - Significant Accounting Policies - Summary  HTML     54K 
                of Cash Equivalents and Short-term Investment                    
                (Details)                                                        
52: R39         Note 2 - Significant Accounting Policies -          HTML     33K 
                Inventory Balance (Details)                                      
53: R40         Note 2 - Significant Accounting Policies - Other    HTML     31K 
                Current Assets (Details)                                         
54: R41         Note 3 - Accounts Receivable (Details Textual)      HTML     26K 
55: R42         Note 3 - Accounts Receivable - Schedule of          HTML     36K 
                Accounts Receivable, Net (Details)                               
56: R43         Note 4 - Prepaid Expenses and Other - Prepaid       HTML     45K 
                Expenses and Other (Details)                                     
57: R44         Note 5 - Property and Equipment (Details Textual)   HTML     26K 
58: R45         Note 5 - Property and Equipment - Property and      HTML     39K 
                Equipment, Net (Details)                                         
59: R46         Note 6 - Leases (Details Textual)                   HTML     47K 
60: R47         Note 6 - Leases - Future Minimum Lease Payments     HTML     36K 
                Under ASC 842 (Details)                                          
61: R48         Note 6 - Leases - Future Minimum Lease Payments to  HTML     32K 
                be Received (Details)                                            
62: R49         Note 6 - Leases - Supplemental Cash Flow            HTML     33K 
                Information Related to Leases (Details)                          
63: R50         Note 7 - Intangible Assets - Intangible Assets,     HTML     30K 
                Net (Details)                                                    
64: R51         Note 7 - Intangible Assets - Future Amortization    HTML     40K 
                Expense Maturity (Details)                                       
65: R52         Note 8 - Accrued Expenses (Details Textual)         HTML     48K 
66: R53         Note 8 - Accrued Expenses - Composition of Current  HTML     55K 
                and Long-term Accrued Expenses (Details)                         
67: R54         Note 9 - Debt (Details Textual)                     HTML     67K 
68: R55         Note 9 - Debt - Schedule of Long Term Debt          HTML     33K 
                (Details)                                                        
69: R56         Note 9 - Debt - Schedule of Long Term Debt          HTML     26K 
                (Details) (Parentheticals)                                       
70: R57         Note 9 - Debt - Future Minimum Principal Payments   HTML     36K 
                (Details)                                                        
71: R58         Note 9 - Debt - Schedule of Debt Issuance Costs     HTML     32K 
                and Discounts (Details)                                          
72: R59         Note 10 - Stockholders' Equity (Deficit) (Details   HTML     98K 
                Textual)                                                         
73: R60         Note 10 - Stockholders' Equity (Deficit) - Fair     HTML     34K 
                Value Options Weighted-Average Assumptions                       
                (Details)                                                        
74: R61         Note 10 - Stockholders' Deficit (Deficit) -         HTML     34K 
                Options Award Assumptions (Details)                              
75: R62         Note 10 - Stockholders' Equity (Deficit) -          HTML     35K 
                Stock-based Compensation Expense (Details)                       
76: R63         Note 10 - Stockholders' Equity (Deficit) - Stock    HTML     67K 
                Option Activity (Details)                                        
77: R64         Note 10 - Stockholders' Equity (Deficit) - Stock    HTML     37K 
                Options Rollforward (Details)                                    
78: R65         Note 10 - Stockholders' Equity (Deficit) -          HTML     47K 
                Restricted Stock Units (Details)                                 
79: R66         Note 11 - 401(k) Savings Plan (Details Textual)     HTML     31K 
80: R67         Note 12 - Income Taxes (Details Textual)            HTML     42K 
81: R68         Note 12 - Income Taxes - Schedule of Income Tax     HTML     44K 
                Expense (Details)                                                
82: R69         Note 12 - Income Taxes - Schedule of Income Tax     HTML     44K 
                Reconciliation (Details)                                         
83: R70         Note 12 - Income Taxes - Components of Net          HTML     60K 
                Deferred Tax Assets (Details)                                    
84: R71         Note 12 - Income Taxes - Reconciliation of          HTML     31K 
                Unrecognized Tax Benefits (Details)                              
85: R72         Note 13 - Commitments and Contingencies (Details    HTML     75K 
                Textual)                                                         
87: XML         IDEA XML File -- Filing Summary                      XML    165K 
90: XML         XBRL Instance -- pbyi20231231_10k_htm                XML   1.98M 
86: EXCEL       IDEA Workbook of Financial Report Info              XLSX    145K 
10: EX-101.CAL  XBRL Calculations -- pbyi-20231231_cal               XML    229K 
11: EX-101.DEF  XBRL Definitions -- pbyi-20231231_def                XML   1.42M 
12: EX-101.LAB  XBRL Labels -- pbyi-20231231_lab                     XML   1.26M 
13: EX-101.PRE  XBRL Presentations -- pbyi-20231231_pre              XML   1.47M 
 9: EX-101.SCH  XBRL Schema -- pbyi-20231231                         XSD    227K 
88: JSON        XBRL Instance as JSON Data -- MetaLinks              535±   863K 
89: ZIP         XBRL Zipped Folder -- 0001437749-24-006121-xbrl      Zip    612K

‘EX-101.CAL’ — XBRL Calculations — pbyi-20231231_cal

This Exhibit is an XBRL File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-maturity-details" xlink:href="pbyi-20231231.xsd#statement-note-7-intangible-assets-future-amortization-expense-maturity-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-7-intangible-assets-future-amortization-expense-maturity-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-schedule-of-income-tax-reconciliation-details" xlink:href="pbyi-20231231.xsd#statement-note-12-income-taxes-schedule-of-income-tax-reconciliation-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-schedule-of-income-tax-reconciliation-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>

<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="pbyi-20231231.xsd#statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" xlink:href="pbyi-20231231.xsd#statement-note-2-significant-accounting-policies-inventory-balance-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-inventory-balance-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-other-current-assets-details" xlink:href="pbyi-20231231.xsd#statement-note-2-significant-accounting-policies-other-current-assets-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-2-significant-accounting-policies-other-current-assets-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_CaresActCreditReceivable" xlink:label="pbyi_CaresActCreditReceivable" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_ReceivableOther" xlink:label="pbyi_ReceivableOther" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_ReimbursementRecieavble" xlink:label="pbyi_ReimbursementRecieavble" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="pbyi_CaresActCreditReceivable" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="pbyi_ReimbursementRecieavble" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="pbyi_ReceivableOther" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-3-accounts-receivable-schedule-of-accounts-receivable-net-details" xlink:href="pbyi-20231231.xsd#statement-note-3-accounts-receivable-schedule-of-accounts-receivable-net-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-3-accounts-receivable-schedule-of-accounts-receivable-net-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_RoyaltyRevenueReceivable" xlink:label="pbyi_RoyaltyRevenueReceivable" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_TradeAccountsReceivableNetExcludingLicenseRevenueReceivable" xlink:label="pbyi_TradeAccountsReceivableNetExcludingLicenseRevenueReceivable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="pbyi_TradeAccountsReceivableNetExcludingLicenseRevenueReceivable" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="pbyi_RoyaltyRevenueReceivable" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableGross" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-net-details" xlink:href="pbyi-20231231.xsd#statement-note-5-property-and-equipment-property-and-equipment-net-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-5-property-and-equipment-property-and-equipment-net-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-6-leases-future-minimum-lease-payments-under-asc-842-details" xlink:href="pbyi-20231231.xsd#statement-note-6-leases-future-minimum-lease-payments-under-asc-842-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-6-leases-future-minimum-lease-payments-under-asc-842-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-6-leases-future-minimum-lease-payments-to-be-received-details" xlink:href="pbyi-20231231.xsd#statement-note-6-leases-future-minimum-lease-payments-to-be-received-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-6-leases-future-minimum-lease-payments-to-be-received-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-7-intangible-assets-intangible-assets-net-details" xlink:href="pbyi-20231231.xsd#statement-note-7-intangible-assets-intangible-assets-net-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-7-intangible-assets-intangible-assets-net-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-9-debt-future-minimum-principal-payments-details" xlink:href="pbyi-20231231.xsd#statement-note-9-debt-future-minimum-principal-payments-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-9-debt-future-minimum-principal-payments-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-9-debt-schedule-of-debt-issuance-costs-and-discounts-details" xlink:href="pbyi-20231231.xsd#statement-note-9-debt-schedule-of-debt-issuance-costs-and-discounts-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-9-debt-schedule-of-debt-issuance-costs-and-discounts-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross" xlink:label="pbyi_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="pbyi_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsGross" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-balance-sheets-" xlink:href="pbyi-20231231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-balance-sheets-" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedInlicensedRightsCurrent" xlink:label="pbyi_AccruedInlicensedRightsCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedLiabilitiesNoncurrent" xlink:label="pbyi_AccruedLiabilitiesNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PostMarketingCommitmentLiabilityCurrent" xlink:label="pbyi_PostMarketingCommitmentLiabilityCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PostmarketingCommitmentLiabilityNoncurrent" xlink:label="pbyi_PostmarketingCommitmentLiabilityNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pbyi_AccruedInlicensedRightsCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pbyi_PostMarketingCommitmentLiabilityCurrent" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="pbyi_AccruedLiabilitiesNoncurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="pbyi_PostmarketingCommitmentLiabilityNoncurrent" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="pbyi-20231231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AcquiredInprocessResearchAndDevelopment" xlink:label="pbyi_AcquiredInprocessResearchAndDevelopment" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet" xlink:label="pbyi_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_IncreaseDecreaseInPostmarketingCommitmentLiability" xlink:label="pbyi_IncreaseDecreaseInPostmarketingCommitmentLiability" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_InstallmentPaymentsToAcquireIntangibleAssets" xlink:label="pbyi_InstallmentPaymentsToAcquireIntangibleAssets" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts" xlink:label="pbyi_PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pbyi_AcquiredInprocessResearchAndDevelopment" xlink:type="arc"/>

<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>

<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>

<link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc"/>

<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>

<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" xlink:type="arc"/>

<link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>

<link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pbyi_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet" xlink:type="arc"/>

<link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>

<link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>

<link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc"/>

<link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pbyi_IncreaseDecreaseInPostmarketingCommitmentLiability" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>

<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pbyi_PaymentForDebtExtinguishmentDebtPrepaymentCostAndOtherExtinguishmentCosts" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>

<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pbyi_InstallmentPaymentsToAcquireIntangibleAssets" xlink:type="arc"/>

<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>

<link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-comprehensive-income-loss" xlink:href="pbyi-20231231.xsd#statement-consolidated-statements-of-comprehensive-income-loss" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-comprehensive-income-loss" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" xlink:href="pbyi-20231231.xsd#statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-4-prepaid-expenses-and-other-prepaid-expenses-and-other-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PrepaidCROServicesCurrent" xlink:label="pbyi_PrepaidCROServicesCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PrepaidOtherClinicalDevelopmentCurrent" xlink:label="pbyi_PrepaidOtherClinicalDevelopmentCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PrepaidOtherClinicalDevelopmentExpenseNoncurrent" xlink:label="pbyi_PrepaidOtherClinicalDevelopmentExpenseNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_PrepaidProfessionalFessCurrent" xlink:label="pbyi_PrepaidProfessionalFessCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="pbyi_PrepaidCROServicesCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="pbyi_PrepaidOtherClinicalDevelopmentCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="pbyi_PrepaidProfessionalFessCurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="pbyi_PrepaidOtherClinicalDevelopmentExpenseNoncurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-8-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" xlink:href="pbyi-20231231.xsd#statement-note-8-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-8-accrued-expenses-composition-of-current-and-longterm-accrued-expenses-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedClinicalExpensesCurrent" xlink:label="pbyi_AccruedClinicalExpensesCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedDevelopmentCosts" xlink:label="pbyi_AccruedDevelopmentCosts" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedLegalVerdictExpenseCurrent" xlink:label="pbyi_AccruedLegalVerdictExpenseCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedLegalVerdictExpenseNoncurrent" xlink:label="pbyi_AccruedLegalVerdictExpenseNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedLiabilitiesNoncurrent" xlink:label="pbyi_AccruedLiabilitiesNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedManufacturingCostsCurrent" xlink:label="pbyi_AccruedManufacturingCostsCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedProfessionalFeesLiabilityCurrent" xlink:label="pbyi_AccruedProfessionalFeesLiabilityCurrent" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AccruedVariableConsiderationCurrent" xlink:label="pbyi_AccruedVariableConsiderationCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedLegalVerdictExpenseCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedManufacturingCostsCurrent" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedDevelopmentCosts" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedVariableConsiderationCurrent" xlink:type="arc"/>

<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:type="arc"/>

<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedClinicalExpensesCurrent" xlink:type="arc"/>

<link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pbyi_AccruedProfessionalFeesLiabilityCurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbyi_AccruedLiabilitiesNoncurrent" xlink:to="pbyi_AccruedLegalVerdictExpenseNoncurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbyi_AccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="pbyi_AccruedLiabilitiesNoncurrent" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-schedule-of-income-tax-expense-details" xlink:href="pbyi-20231231.xsd#statement-note-12-income-taxes-schedule-of-income-tax-expense-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-schedule-of-income-tax-expense-details" xlink:type="extended">

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-components-of-net-deferred-tax-assets-details" xlink:href="pbyi-20231231.xsd#statement-note-12-income-taxes-components-of-net-deferred-tax-assets-details" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-note-12-income-taxes-components-of-net-deferred-tax-assets-details" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxAssetLeaseLiabilities" xlink:label="pbyi_DeferredTaxAssetLeaseLiabilities" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxAssetsAccruedLegalVerdict" xlink:label="pbyi_DeferredTaxAssetsAccruedLegalVerdict" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxAssetsBusinessCreditCarryforward" xlink:label="pbyi_DeferredTaxAssetsBusinessCreditCarryforward" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxAssetsLiabilitiesGross" xlink:label="pbyi_DeferredTaxAssetsLiabilitiesGross" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxLiabilitiesAssetsInventory" xlink:label="pbyi_DeferredTaxLiabilitiesAssetsInventory" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_DeferredTaxLiabilitiesLeaseRightOfUseAsset" xlink:label="pbyi_DeferredTaxLiabilitiesLeaseRightOfUseAsset" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pbyi_DeferredTaxAssetLeaseLiabilities" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pbyi_DeferredTaxAssetsAccruedLegalVerdict" xlink:type="arc"/>

<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc"/>

<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>

<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc"/>

<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pbyi_DeferredTaxAssetsBusinessCreditCarryforward" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="pbyi_DeferredTaxLiabilitiesLeaseRightOfUseAsset" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="pbyi_DeferredTaxLiabilitiesAssetsInventory" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbyi_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbyi_DeferredTaxAssetsLiabilitiesGross" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="pbyi_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>

</link:calculationLink>

<link:roleRef roleURI="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-operations" xlink:href="pbyi-20231231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>

<link:calculationLink xlink:role="http://www.pumabiotechnology.com/20231231/role/statement-consolidated-statements-of-operations" xlink:type="extended">

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_AcquiredInprocessResearchAndDevelopment" xlink:label="pbyi_AcquiredInprocessResearchAndDevelopment" xlink:type="locator"/>

<link:loc xlink:href="pbyi-20231231.xsd#pbyi_LegalVerdictExpenseCredit" xlink:label="pbyi_LegalVerdictExpenseCredit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator"/>

<link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="pbyi_AcquiredInprocessResearchAndDevelopment" xlink:type="arc"/>

<link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>

<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="pbyi_LegalVerdictExpenseCredit" xlink:type="arc"/>

<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:type="arc"/>

<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>

<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>

<link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>

<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>

</link:calculationLink>

</link:linkbase>

44 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/02/23  Puma Biotechnology, Inc.          10-Q        9/30/23   80:7.4M                                   RDG Filings/FA
 8/18/23  Puma Biotechnology, Inc.          8-K:5,9     8/17/23   12:348K                                   RDG Filings/FA
 8/03/23  Puma Biotechnology, Inc.          10-Q        6/30/23   80:7.4M                                   RDG Filings/FA
 3/02/23  Puma Biotechnology, Inc.          10-K       12/31/22   92:10M                                    RDG Filings/FA
11/03/22  Puma Biotechnology, Inc.          10-Q        9/30/22   84:7.8M                                   RDG Filings/FA
 5/05/22  Puma Biotechnology, Inc.          10-Q        3/31/22   80:6.6M                                   RDG Filings/FA
 3/03/22  Puma Biotechnology, Inc.          10-K       12/31/21   94:9.5M                                   RDG Filings/FA
11/04/21  Puma Biotechnology, Inc.          8-K:1,9    11/04/21   13:455K                                   RDG Filings/FA
11/04/21  Puma Biotechnology, Inc.          10-Q        9/30/21   84:8.4M                                   RDG Filings/FA
 9/16/21  Puma Biotechnology, Inc.          S-8         9/16/21    5:119K                                   Donnelley … Solutions/FA
 6/17/21  Puma Biotechnology, Inc.          8-K:5,9     6/15/21   12:195K                                   Donnelley … Solutions/FA
 5/06/21  Puma Biotechnology, Inc.          10-Q        3/31/21   82:10M                                    ActiveDisclosure/FA
 3/01/21  Puma Biotechnology, Inc.          10-K       12/31/20   96:15M                                    ActiveDisclosure/FA
 8/06/20  Puma Biotechnology, Inc.          10-Q        6/30/20   81:10M                                    ActiveDisclosure/FA
 5/07/20  Puma Biotechnology, Inc.          10-Q        3/31/20   76:8.9M                                   ActiveDisclosure/FA
 2/28/20  Puma Biotechnology, Inc.          10-K       12/31/19   96:14M                                    ActiveDisclosure/FA
 2/28/20  Puma Biotechnology, Inc.          S-8         2/28/20    4:68K                                    Donnelley … Solutions/FA
 5/10/19  Puma Biotechnology, Inc.          10-Q        3/31/19   73:8.3M                                   ActiveDisclosure/FA
 3/01/19  Puma Biotechnology, Inc.          10-K       12/31/18   84:12M                                    ActiveDisclosure/FA
11/09/18  Puma Biotechnology, Inc.          8-K:5,9    11/06/18    2:116K                                   Donnelley … Solutions/FA
 8/09/18  Puma Biotechnology, Inc.          10-Q        6/30/18   63:7.1M                                   ActiveDisclosure/FA
 5/10/18  Puma Biotechnology, Inc.          10-Q        3/31/18   62:7.3M                                   ActiveDisclosure/FA
 3/09/18  Puma Biotechnology, Inc.          10-K       12/31/17   80:12M                                    ActiveDisclosure/FA
 6/14/17  Puma Biotechnology, Inc.          8-K:5,9     6/12/17    3:52K                                    Donnelley … Solutions/FA
 5/31/17  Puma Biotechnology, Inc.          S-8         5/31/17    4:205K                                   Donnelley … Solutions/FA
10/17/16  Puma Biotechnology, Inc.          8-K:5,9    10/14/16    2:47K                                    Donnelley … Solutions/FA
 6/15/16  Puma Biotechnology, Inc.          8-K:5,9     6/13/16    2:42K                                    Donnelley … Solutions/FA
11/09/15  Puma Biotechnology, Inc.          10-Q        9/30/15   53:5.5M                                   ActiveDisclosure/FA
 8/10/15  Puma Biotechnology, Inc.          10-Q        6/30/15   52:5.3M                                   ActiveDisclosure/FA
 3/02/15  Puma Biotechnology, Inc.          10-K       12/31/14   69:12M                                    ActiveDisclosure/FA
11/10/14  Puma Biotechnology, Inc.          10-Q        9/30/14   50:6.6M                                   ActiveDisclosure/FA
 5/23/14  Puma Biotechnology, Inc.          8-K:1,9     5/19/14    2:337K                                   Donnelley … Solutions/FA
 4/30/14  Puma Biotechnology, Inc.          DEF 14A     6/10/14    1:755K                                   Donnelley … Solutions/FA
 3/03/14  Puma Biotechnology, Inc.          10-K       12/31/13   72:6.4M                                   Donnelley … Solutions/FA
 4/01/13  Puma Biotechnology, Inc.          10-K       12/31/12   60:5.6M                                   Donnelley … Solutions/FA
10/15/12  Puma Biotechnology, Inc.          S-1/A                 60:5.7M                                   Donnelley … Solutions/FA
 6/13/12  Puma Biotechnology, Inc.          8-K:1,9     6/07/12    2:1M                                     Donnelley … Solutions/FA
 3/29/12  Puma Biotechnology, Inc.          10-K       12/31/11   34:2M                                     Donnelley … Solutions/FA
 2/01/12  Puma Biotechnology, Inc.          S-1/A                  4:1.7M                                   Donnelley … Solutions/FA
 1/24/12  Puma Biotechnology, Inc.          8-K:5,9     1/19/12    2:122K                                   Donnelley … Solutions/FA
12/16/11  Puma Biotechnology, Inc.          8-K/A:1,2,310/04/11    4:1.2M                                   Donnelley … Solutions/FA
12/13/11  Puma Biotechnology, Inc.          8-K:1,9    12/07/11    2:698K                                   Donnelley … Solutions/FA
10/11/11  Puma Biotechnology, Inc.          8-K:1,2,3,410/04/11   14:1.7M                                   Donnelley … Solutions/FA
10/04/11  Puma Biotechnology, Inc.          8-K:1,9     9/29/11    3:286K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001437749-24-006121 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Puma Biotechnology, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.CAL’

On: Thursday, 2/29/24, at 4:41pm ET · For: 12/31/23 · Accession #: 1437749-24-6121 · File #: 1-35703

Annual Report — Form 10-K — SEA’34Filing Table of Contents

‘EX-101.CAL’ — XBRL Calculations — pbyi-20231231_cal

This Exhibit is an XBRL File.

44 Previous Filings that this Filing References

Annual Report — Form 10-K — SEA’34

Filing Table of Contents